Search results for Zanolimumab

Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade, ProteoGenix, PX-TA1152

Description of Zanolimumab Biosimilar - Anti-CD4 mAb - Research Grade Introduction to Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade Zanolimumab Biosimilar is a novel therapeutic antibody that targets the CD4 protein, a key player in the immune system. This biosimilar is designed to mimic the structure and activity of the original antibody, providing a cost-effective and accessible treatment option for various diseases. In this article, we will explore the structure, activity, and potential applications of Zanolimumab Biosimilar in detail. Structure of Zanolimumab Biosimilar Zanolimumab Biosimilar is a monoclonal antibody (mAb) that is produced by recombinant DNA technology. It is a humanized IgG1 antibody, meaning that it has been engineered to have a human-like structure to reduce the risk of immune reactions. The antibody is composed of two heavy chains and two light chains, each with a unique amino acid sequence. The heavy chains are responsible for binding to the CD4 protein, while the light chains provide stability to the overall structure of the antibody. Activity of Zanolimumab Biosimilar Zanolimumab Biosimilar works by binding to the CD4 protein, which is found on the surface of certain immune cells, including T-helper cells. This binding prevents the CD4 protein from interacting with other immune cells, thereby inhibiting the immune response. This activity is particularly beneficial in diseases where the immune system is overactive, such as autoimmune disorders and inflammatory conditions. Title: Applications of Zanolimumab Biosimilar Zanolimumab Biosimilar has shown promising results in preclinical studies for various diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. In rheumatoid arthritis, the antibody has been shown to reduce inflammation and joint damage by inhibiting the activity of T-helper cells. In psoriasis, Zanolimumab Biosimilar has been found to improve skin lesions and reduce the severity of symptoms by targeting the immune cells responsible for the disease. In multiple sclerosis, the antibody has been shown to delay disease progression by modulating the immune response. Advantages of Zanolimumab Biosimilar Zanolimumab Biosimilar offers several advantages over the original antibody, including lower production costs, increased accessibility, and improved safety profile. As a biosimilar, it is produced using the same manufacturing process as the original antibody, but at a lower cost, making it more affordable for patients. This also allows for increased accessibility to treatment for patients in need. Furthermore, the humanized structure of Zanolimumab Biosimilar reduces the risk of immune reactions, making it a safer option for patients. Conclusion In conclusion, Zanolimumab Biosimilar is a promising therapeutic option for various diseases that target the CD4 protein. Its unique structure and activity make it an effective treatment for conditions where the immune system is overactive. With its lower production costs and improved safety profile, Zanolimumab Biosimilar has the potential to provide accessible and affordable treatment for patients in need. Further clinical trials and studies are needed to fully evaluate the efficacy and safety of this biosimilar, but it holds great promise in the field of immunotherapy.

Zanolimumab, Abbexa, abx831109

Zanolimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD4, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Zanolimumab ELISA Kit, ProteoGenix, KPTX138

Description of Zanolimumab ELISA Kit The Structure of Zanolimumab ELISA Kit Zanolimumab ELISA Kit is a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) kit designed for the quantitative detection of zanolimumab in biological samples. The kit is composed of several components including a microplate coated with a monoclonal antibody specific for zanolimumab, a zanolimumab standard, and a detection antibody labeled with an enzyme. The microplate is made of high-quality polystyrene and is divided into 96 wells, each of which is coated with the monoclonal antibody. This antibody is designed to specifically bind to zanolimumab, ensuring the accuracy and specificity of the assay. The zanolimumab standard is a known concentration of the therapeutic antibody, which is used to generate a standard curve for the quantification of zanolimumab in the sample. The detection antibody is labeled with an enzyme, which allows for the visualization and quantification of zanolimumab in the sample. The enzyme used in the kit is horseradish peroxidase (HRP), which catalyzes a colorimetric reaction upon the addition of a substrate. This reaction produces a color change that is directly proportional to the amount of zanolimumab present in the sample. The Activity of Zanolimumab ELISA Kit Zanolimumab ELISA Kit is a highly sensitive and specific assay that utilizes the principle of sandwich ELISA. This technique involves the capture of zanolimumab by the monoclonal antibody coated on the microplate, followed by the detection of zanolimumab using the labeled detection antibody. The colorimetric reaction produced by the enzyme allows for the quantification of zanolimumab in the sample. The kit has a high sensitivity, with a lower limit of detection of 0.1 ng/mL. This means that even low concentrations of zanolimumab can be accurately detected and quantified. The assay also has a wide dynamic range of 0.2-100 ng/mL, allowing for the detection of both low and high levels of zanolimumab in the sample. The activity of the kit is not affected by the presence of other therapeutic antibodies or proteins in the sample, ensuring the accuracy and specificity of the results. The assay also has a high reproducibility, with a coefficient of variation (CV) of less than 10%. The Application of Zanolimumab ELISA Kit Zanolimumab ELISA Kit has a wide range of applications in the field of therapeutic antibody research and development. It can be used for the quantitative detection of zanolimumab in various biological samples, including serum, plasma, and cell culture supernatants. One of the main applications of the kit is in the pharmacokinetic (PK) and pharmacodynamic (PD) studies of zanolimumab. The accurate quantification of zanolimumab levels in the sample can provide valuable information on the absorption, distribution, metabolism, and excretion of the therapeutic antibody. It can also help in determining the optimal dosage and dosing frequency of zanolimumab for maximum efficacy. Zanolimumab ELISA Kit can also be used for the screening and characterization of zanolimumab in hybridoma cell lines and in the purification process of zanolimumab. It can aid in the development and optimization of production processes, ensuring the quality and consistency of zanolimumab. In addition, the kit can also be used in clinical trials to monitor zanolimumab levels in patients receiving treatment. This can help in evaluating the efficacy of the therapeutic antibody and in determining the appropriate treatment regimen for individual patients. In conclusion, Zanolimumab ELISA Kit is a highly sensitive and specific assay that is essential for the accurate quantification of zanolimumab in various biological samples. Its wide range of applications makes it a valuable tool in therapeutic antibody research and development, aiding in the development of effective treatments for various diseases.

Zanolimumab ELISA Kit, Abbexa, abx395027

Zanolimumab ELISA Kit is a quantitative ELISA kit for detection of Zanolimumab.Zanolimumab is a biosimilar that targets CD4. The CD4 antigen is involved in the recognition of MHC class II molecules and is a co-receptor for HIV. CD4 is primarily expressed in a subset of T-lymphocytes, also referred to as T helper cells, but may also be expressed by other cells in the immune system, such as monocytes, macrophages, and dendritic cells. At the tissue level, CD4 expression may be detected in thymus, lymph nodes, tonsils, and spleen, and also in specific regions of the brain, gut, and other non-lymphoid tissues. CD4 functions to initiate or augment the early phase of T-cell activation through its association with the T-cell receptor complex and protein tyrosine kinase, Lck. It may also function as an important mediator of direct neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcripts have been identified in this gene [RefSeq, July 2017].

Research Grade Zanolimumab (HF998026), abinScience, HF998026